Open AccessU.S. Food and Drug Administration Approval: Peginterferon‐alfa‐2b for the Adjuvant Treatment of Patients with Melanoma
Author(s) -
Herndon Thomas M.,
Demko Suzanne G.,
Jiang Xiaoping,
He Kun,
Gootenberg Joseph E.,
Cohen Martin H.,
Keegan Patricia,
Pazdur Richard
Publication year - 2012
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1634/theoncologist.2012-0123
Subject(s) - medicine , adverse effect , melanoma , clinical endpoint , adjuvant , surgery , food and drug administration , clinical trial , gastroenterology , pharmacology , cancer research
Learning Objectives After completing this course, the reader will be able to: Describe the setting in which the use of peginterferon‐alfa‐2b is appropriate for melanoma patients. Define the expectations with regard to survival and side effect profile in patients with melanoma receiving peginterferon‐alfa‐2b.This article is available for continuing medical education credit at CME.TheOncologist.com On March 29, 2011, the U.S. Food and Drug Administration approved peginterferon alfa‐2b (PEG‐IFN) (Sylatron™; Schering Corporation, Kenilworth, NJ) for the adjuvant treatment of melanoma patients with microscopic or gross nodal involvement following definitive surgical resection including complete lymphadenectomy. The approval was based on a single, open‐label, multicenter trial enrolling 1,256 patients. After surgical resection, patients were randomized (1:1) to either PEG‐IFN or observation for 5 years. PEG‐IFN, 6 μg/kg per week, was administered s.c. for eight doses, followed by 3 μg/kg per week for up to 252 weeks. Stratification factors included microscopic or gross nodal involvement, number of positive nodes, Breslow thickness, ulceration, sex, and study center. Patients were assessed for recurrence by the investigators based on physical examination every 3 months for 2 years and every 6 months thereafter. The relapse‐free survival (RFS) interval, the primary efficacy endpoint, was significantly longer in PEG‐IFN–treated patients. The median RFS times were 34.8 months and 25.5 months, respectively. There was no statistically significant difference in the overall survival time. The most common (>60%) grade 1–4 adverse reactions were fatigue, increased alanine aminotransferase (ALT) and aspartate aminotransferase (AST), pyrexia, headache, anorexia, myalgia, nausea, chills, and injection site reactions. The most common serious adverse reactions were fatigue, increased ALT and AST, and pyrexia. Thirty‐three percent of patients receiving PEG‐IFN discontinued treatment as a result of adverse reactions. Five deaths were reported within 30 days of the last treatment dose, two resulting from cardiovascular disease considered as possibly related to treatment.